Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 14,938 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disease Clear all
Recruiting No phase listed Observational

Protoacoustic Imaging For 3D Mapping

NCT07832617
View directory record Official record
Conditions
Proton Therapy, Radiation Therapy, Secondary Skin Reactions, Liver Cancer, Prostate Cancer
Interventions
Radiacoustic Imaging w/Ultrasound.
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
24 participants
Timeline
2026 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Not applicable Interventional

Regional Native American Community Networks Program (RNACNP)

NCT02843217
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Lifestyle, screening
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
50 Years to 75 Years
Enrollment
1,458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Pullman, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Active, not recruiting Phase 1 Interventional

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Interventions
RMC-6291
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Springdale, Arkansas • Orange, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Withdrawn No phase listed Observational

Clinical Outcomes in Hereditary Cancer

NCT00580021
View directory record Official record
Conditions
Breast Cancer, Pancreatic Cancer
Interventions
Genotyping
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 22, 2026, 4:32 PM EDT
Terminated Not applicable Interventional Results available

Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer

NCT01284504
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer
Interventions
Celecoxib, placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 22, 2026, 4:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"

NCT04144738
View directory record Official record
Conditions
Colorectal Cancer
Interventions
mt-sDNA 2.0 screening test, FIT test, Colonoscopy
Diagnostic Test · Procedure
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
40 Years and older
Enrollment
26,758 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
195
States / cities
Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 22, 2026, 4:32 PM EDT
Completed No phase listed Observational

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

NCT02932449
View directory record Official record
Conditions
Biliary Cirrhosis, Primary
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
39
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Not applicable Interventional

Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer

NCT03233555
View directory record Official record
Conditions
Stage I Breast Cancer, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Prostate Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage II Colorectal Cancer AJCC v7, Stage II Prostate Cancer, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer AJCC v7, Stage IIA Prostate Cancer, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer AJCC v7, Stage IIB Prostate Cancer, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7
Interventions
Informational Intervention, Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 22, 2026, 4:32 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reducing Fatigue With CoQ10 Supplementation in Patients With Crohn's Disease Study

NCT06419335
View directory record Official record
Conditions
Crohn Disease, Healthy
Interventions
CoQ10
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Withdrawn Phase 2 Interventional

Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

NCT00954876
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
capecitabine and cetuximab
Drug
Lead sponsor
Translational Genomics Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 22, 2026, 4:32 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease

NCT01739517
View directory record Official record
Conditions
Short Bowel Syndrome, Cholestasis
Interventions
Omegaven Therapy
Drug
Lead sponsor
Amarnath, Rathna, M.D.
Individual
Eligibility
Up to 1 Year
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 22, 2026, 4:32 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Mayo Clinic IBD Biobank

NCT03756649
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Blood Draw, Urine Collection, Stool Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2065
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

NCT01369355
View directory record Official record
Conditions
Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
Interventions
Placebo SC, Placebo IV, Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
77
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 22, 2026, 4:32 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

NCT00640978
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
RAD001, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04477343
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Interventions
SX-682, Nivolumab Injectable Product
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparison of Voice Therapy and Antireflex Therapy in LPR

NCT02530879
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Omeprazole, Lansoprazole, Esomeprazole, Rantidine, Voice therapy, Combination of anti-reflux medication and voice therapy
Drug · Behavioral · Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 22, 2026, 4:32 PM EDT
Withdrawn Phase 2 Interventional

Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)

NCT02766842
View directory record Official record
Conditions
Mesenchymal Tumor, Autoimmune Pancreatitis, Lymphoma, Solid Tumors
Interventions
EUS-FNB with ProCore needle, EUS-FNB with SharkCore needle, ProCore needle, SharkCore needle
Procedure · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

NCT02514473
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-809, Placebo, VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 1 Interventional

A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy

NCT01218854
View directory record Official record
Conditions
Lung Neoplasms, Liver Neoplasms, Kidney Neoplasms, Cancer
Interventions
Needle angle measurement
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Not applicable Interventional

Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial (EDGE Trial)

NCT01515501
View directory record Official record
Conditions
Constipation, Hirschsprung Disease
Interventions
Endoscopic mucosal resection (EMR)
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 22, 2026, 4:32 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Decision Support Tool for Pancreatic Cancer Screening -Aim 2

NCT07808671
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Electronic Decision Support Tool
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Terminated Not applicable Interventional

Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.

NCT00159471
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
capecitabine, gemcitabine, docetaxel
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 22, 2026, 4:32 PM EDT
Recruiting Phase 2 Interventional

Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

NCT06638944
View directory record Official record
Conditions
Dysphagia, Stroke, Parkinson Disease
Interventions
In-person sEMG-biofeedback, Remote sEMG-biofeedback, Standard-of-care treatment
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
50 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Champaign, Illinois • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)

NCT00373334
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, GERD, Heartburn
Interventions
nizatidine (axid), placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
30 Days to 1 Year
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Hot Springs, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2009 · Synced Oct 22, 2026, 4:32 PM EDT